Is Dr. Lal Pathlabs a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that Dr. Lal Pathlabs Ltd is a good quality company .

Is Dr. Lal Pathlabs undervalued or overvalued?

The key valuation ratios of Dr. Lal Pathlabs Ltd's currently when compared to its past seem to suggest it is in the Fair zone .

What is Dr. Lal Pathlabs share price return in the past 10 years?

Data is not available for this company

Is Dr. Lal Pathlabs a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Dr. Lal Pathlabs Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

Dr. Lal Pathlabs Ltd - Stock Valuation and Financial Performance

Name: Dr. Lal Pathlabs
Brand: Dr. Lal Pathlabs

BSE: 539524 | NSE: LALPATHLAB | Hospital & Healthcare Services | Small Cap

Place order

Dr. Lal Pathlabs Share Price

₹2,972.35 -46.55 -1.54%
as on 03-Dec'24 16:59

10 Year X-Ray of Dr. Lal Pathlabs:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Standalone Basis ^P Consolidated Basis ^P

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

Value Creation Index Colour Code Guide ⓘ

	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	TTM
ROCE % ⓘ	50.7%	48.2%	43.5%	37.7%	34.3%	32.6%	34.8%	32.3%	22.7%	27.8%	-
Value Creation Index ⓘ	3.5	2.6	2.2	1.8	1.5	1.4	1.6	1.9	0.7	1.1	-
Growth Parameters ⓘ Growth Parameters Colour Code Guide ⓘ
Sales ⓘ	637	765	882	1,024	1,165	1,274	1,491	1,879	1,769	1,967	2,073
Sales YoY Gr.	-	20.2%	15.2%	16.1%	13.8%	9.3%	17%	26.1%	-5.8%	11.2%	-
Adj EPS ⓘ	16.8	15.2	18.4	20.1	23.2	26.1	33.6	41.8	34.9	46	52.2
YoY Gr.	-	-9.5%	21%	9.4%	15.1%	12.7%	28.8%	24.2%	-16.4%	31.7%	-
BVPS (₹) ⓘ	53.6	57.9	69.6	91	108.3	118	141.3	169.7	195.7	221.5	248.2
Adj Net Profit ⓘ	91.8	126	153	168	193	218	280	348	291	384	436
Cash Flow from Ops. ⓘ	94.1	142	167	189	209	272	373	426	428	478	-
Debt/CF from Ops. ⓘ	0	0	0	0	0	0	0	0.8	0.6	0.2	-

CAGR ⓘ

CAGR Colour Code Guide ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	13.4%	11%	9.7%	11.2%
Adj EPS ⓘ	11.9%	14.7%	11%	31.7%
BVPSⓘ	17.1%	15.4%	16.2%	13.1%
Share Price	-	12.6%	-7.1%	8.5%

Key Financial Parameters ⓘ

Performance Ratio Colour Code Guide ⓘ

	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	TTM
Return on Equity % ⓘ	34.3	31.5	28.7	24.6	22.6	22.3	25.1	25.9	18.4	21.4	22.2
Op. Profit Mgn % ⓘ	23.6	26.4	26.1	25	24.3	25.7	27.3	27.5	26	28.4	29
Net Profit Mgn % ⓘ	14.4	16.4	17.3	16.4	16.6	17.1	18.8	18.5	16.5	19.5	21
Debt to Equity ⓘ	0	0	0	0	0	0	0	0.2	0.2	0.1	0
Working Cap Days ⓘ	53	66	66	66	62	52	45	36	38	35	86
Cash Conv. Cycle ⓘ	-14	-15	-10	-12	-13	-15	-21	-19	-21	-27	50

Recent Performance Summary

Return on Equity has increased versus last 3 years average to 22.20%

Net Profit is growing at healthy rate in last 3 years 11.03%

Sales growth is good in last 4 quarters at 10.79%

Sales growth has been subdued in last 3 years 9.68%

Latest Financials - Dr. Lal Pathlabs Ltd.

	Standalone	Consolidated
TTM EPS (₹)	52.2	48
TTM Sales (₹ Cr.)	2,073	2,346
BVPS (₹.) ⓘ	248.2	239.5
Reserves (₹ Cr.) ⓘ	1,991	1,918
P/BV ⓘ	12.16	12.61
PE ⓘ	57.88	62.86

From the Market
52 Week Low / High (₹)	1943.20 / 3645.00
All Time Low / High (₹)	696.50 / 4243.00
Market Cap (₹ Cr.)	25,232
Equity (₹ Cr.)	83.6
Face Value (₹)	10
Industry PE ⓘ	41.8

Management X-Ray of Dr. Lal Pathlabs:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

0.00

* Pledged shares as % of Promoter's holding (%)

Valuation of Dr. Lal Pathlabs

Price Calculator

Price Chart

Price to Earnings

Enterprise Value to EBIT

Price to Book-Value

Price to Sales

Dividend History

Analyst's Notes

This is a premium feature, Please click here to check our solutions.

Key Ratios of Dr. Lal Pathlabs

Standalone Basis Consolidated Basis

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Sales	637	765	882	1,024	1,165	1,274	1,491	1,879	1,769	1,967
Operating Expenses ⓘ	487	564	652	768	882	946	1,083	1,366	1,308	1,408
Manufacturing Costs	23	30	147	178	205	233	267	363	380	414
Material Costs	135	168	191	219	255	287	374	448	390	391
Employee Cost	131	133	147	175	202	232	257	321	316	364
Other Costs ⓘ	198	232	166	195	220	193	185	234	224	239
Operating Profit ⓘ	150	202	230	256	283	328	407	512	461	559
Operating Profit Margin (%)	23.6%	26.4%	26.1%	25.0%	24.3%	25.7%	27.3%	27.3%	26.0%	28.4%
Other Income ⓘ	17	22	28	32	46	58	51	53	47	60
Interest ⓘ	0	0	1	1	1	15	15	29	34	27
Depreciation ⓘ	32	32	26	31	36	68	70	76	82	77
Exceptional Items ⓘ	0	0	0	0	0	0	0	0	0	0
Profit Before Tax ⓘ	135	192	231	256	292	303	374	461	391	516
Tax ⓘ	44	66	79	87	97	80	94	116	98	132
Profit After Tax	92	126	152	168	195	223	280	345	292	384
PAT Margin (%)	14.4%	16.4%	17.3%	16.4%	16.8%	17.5%	18.8%	18.4%	16.5%	19.5%
Adjusted EPS (₹)	16.1	15.2	18.4	20.2	23.5	26.8	33.6	41.4	35.1	46.0
Dividend Payout Ratio (%)	10%	16%	16%	22%	26%	45%	60%	29%	34%	52%

Balance Sheet

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Equity and Liabilities
Shareholders Fund	319	479	578	759	903	983	1,177	1,415	1,632	1,849
Share Capital ⓘ	81	83	83	83	83	83	83	83	83	83
Reserves ⓘ	238	396	495	675	819	900	1,094	1,331	1,548	1,765
Minority Interest	0	0	0	0	0	0	0	0	0	0
Debt	0	0	0	0	0	0	0	262	153	0
Long Term Debt	0	0	0	0	0	0	0	167	83	0
Short Term Debt	0	0	0	0	0	0	0	95	70	0
Trade Payables	33	41	51	62	77	113	136	123	140	167
Others Liabilities ⓘ	72	61	35	58	65	200	233	380	362	361
Total Liabilities ⓘ	424	580	663	879	1,045	1,296	1,546	2,181	2,288	2,377
Fixed Assets
Gross Block	267	307	147	226	262	449	520	667	736	749
Accumulated Depreciation	148	177	26	54	89	152	220	296	374	440
Net Fixed Assetsⓘ	119	130	121	173	173	297	300	371	361	309
CWIP ⓘ	1	4	17	9	3	11	9	14	5	6
Investmentsⓘ	49	74	134	174	214	253	171	1,062	1,213	1,143
Inventories	14	14	17	27	28	55	39	40	23	28
Trade Receivables	29	35	40	40	53	50	64	67	63	78
Cash Equivalents ⓘ	145	207	235	307	478	549	889	543	534	683
Others Assetsⓘ	66	117	98	150	97	81	75	84	87	131
Total Assets ⓘ	424	580	663	879	1,045	1,296	1,546	2,181	2,288	2,377

Cash Flow

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Cash Flow From Operating Activity ⓘ	94	142	167	189	209	272	373	426	428	478
PBT ⓘ	131	192	152	256	292	303	374	461	391	516
Adjustment ⓘ	47	11	90	17	9	46	59	88	96	64
Changes in Working Capital ⓘ	-32	6	-8	8	10	13	37	-6	40	23
Tax Paid ⓘ	-52	-67	-68	-92	-102	-89	-97	-118	-99	-125
Cash Flow From Investing Activity ⓘ	-86	-148	-134	-166	-93	-19	-195	-449	-288	32
Capex	-31	-42	-49	-66	-39	-48	-35	-68	-38	-48
Net Investments	-67	-111	-92	-118	-79	47	-174	512	-268	40
Others ⓘ	12	5	7	18	25	-18	14	-892	17	40
Cash Flow From Financing Activityⓘ	1	1	-32	13	-54	-187	-136	141	-270	-404
Net Proceeds from Shares ⓘ	11	17	4	44	0	0	0	0	1	3
Net Proceeds from Borrowing ⓘ	0	0	0	0	0	0	0	0	-83	-83
Interest Paid ⓘ	0	-1	0	0	0	-15	-15	-29	-34	-27
Dividend Paid ⓘ	-6	-15	-37	-31	-54	-153	-99	-116	-99	-199
Others ⓘ	-4	0	1	0	0	-19	-22	286	-54	-98
Net Cash Flow ⓘ	9	-5	1	36	61	65	42	118	-131	106

Finance Ratio

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Ratios
ROE (%)	38.09	32.62	28.87	25.18	23.53	23.66	25.93	26.64	19.19	22.09
ROCE (%)	50.72	48.15	43.53	37.65	34.34	32.6	34.82	32.27	22.71	27.77
Asset Turnover Ratio	1.73	1.52	1.42	1.33	1.21	1.09	1.05	1.01	0.79	0.84
PAT to CFO Conversion(x)	1.02	1.13	1.1	1.13	1.07	1.22	1.33	1.23	1.47	1.24
Working Capital Days
Receivable Days	15	15	16	14	15	15	14	13	13	13
Inventory Days	7	7	6	8	9	12	12	8	7	5
Payable Days	88	80	87	94	100	121	121	106	123	144

Dr. Lal Pathlabs Ltd Stock News

Dr. Lal Pathlabs Ltd FAQs

What is the share price of Dr. Lal Pathlabs?

Company share prices are keep on changing according to the market conditions. The closing price of Dr. Lal Pathlabs on 03-Dec-2024 16:59 is ₹2,972.4.

What is the market cap of Dr. Lal Pathlabs?

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 03-Dec-2024 16:59 the market cap of Dr. Lal Pathlabs stood at ₹25,231.7.

What is the P/E ratio of Dr. Lal Pathlabs?

The latest P/E ratio of Dr. Lal Pathlabs as of 03-Dec-2024 16:59 is 57.88.

What is the P/B ratio of Dr. Lal Pathlabs?

The latest P/B ratio of Dr. Lal Pathlabs as of 03-Dec-2024 16:59 is 12.16.

What is the 52-week high and low of Dr. Lal Pathlabs?

The 52-week high of Dr. Lal Pathlabs is ₹3,645 and the 52-week low is ₹1,943.2.

What is the TTM revenue of Dr. Lal Pathlabs?

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Dr. Lal Pathlabs is ₹2,073 ( Cr.) .

About Dr. Lal Pathlabs Ltd

The company was incorporated as ‘Dr. Lal PathLabs Private Limited’, a private limited company under the Companies Act, 1956, with a certificate of incorporation issued by the Registrar of Companies, National Capital Territory of Delhi and Haryana (RoC) on February 14, 1995 at Delhi. Subsequently, the name of the company was changed to ‘Dr. Lal PathLabs Limited’ upon conversion of the company into a public limited company pursuant to a special resolution of the shareholders of the company dated August 7, 2015 and a fresh certificate of incorporation was issued by the RoC on August 19, 2015. There has been no change in the registered office of the company since incorporation of the company.

The company focuses on providing patients quality diagnostic and related healthcare tests and services. The company’s focus on the patient as a customer is a critical differentiator in the diagnostic and healthcare industries and, together with what its brand’s recognition for quality diagnostic services, results in individuals and healthcare providers choosing it as their diagnostic healthcare service provider. This is because (i) in India, patients generally choose their diagnostic healthcare service provider and (ii) patients and healthcare providers seek quality healthcare service providers due to what range in quality and reliability of diagnostic healthcare services in India.

With over 3,368 diagnostic and related healthcare tests and services offered, the company is capable of performing substantially all of the diagnostic healthcare tests and services currently prescribed by physicians in India. Its diagnostic and related healthcare tests and services include (i) routine clinical laboratory tests - such as blood chemistry analyses and blood cell counts; (ii) specialized testing services - such as histopathology analyses, genetic marker-based tests, viral and bacterial cultures and infectious disease tests; and (iii) preventive testing services - such as screenings for hypertension, heart disease and diabetes. It performs these tests and services in its clinical laboratories using sophisticated and computerized instruments.

The company has built a national, “hub and spoke” network that includes its National Reference Laboratory in New Delhi. The company’s “hub and spoke” model, whereby specimens are collected across multiple locations within a region for delivery to a predesignated clinical laboratory for centralized diagnostic testing, provides greater economies of scale and offers a scalable platform for the continued growth of its business. Its network is present across India, including large cities such as New Delhi, Mumbai, Bengaluru, Chennai, Hyderabad and Kolkata. The company’s centralized information technology platform fully integrates its large network through a common logistics and payments system and tracks its operations and internal performance metrics, thereby enabling it to improve the efficiencies of its business.

Business area of the company

The company is a provider of diagnostic and related healthcare tests and services in India. Through its integrated, nationwide network, the company offers patients and healthcare providers a broad range of diagnostic and related healthcare tests and services for use in core testing, patient diagnosis and the prevention, monitoring and treatment of disease and other health conditions. Its customers include individual patients, hospitals and other healthcare providers and corporate customers.

Awards and accreditations

2001: Received the ISO 9001:2008 certification for the quality management system for performance of routine and advanced diagnostic pathology testing services, including in clinical trials.
2002: Fully accredited by the College of American Pathologists’ Laboratory Accreditation Program.
2008: Awarded the CNBC TV18 Emerging India Award 2008 by ICICI Bank Business Banking in the pharmaceuticals and chemicals category.
2010: Franchisor of the Year in healthcare, at the Franchise Plus Awards.
2010: Honourable mention in the healthcare category at the Milagrow Trailblazers Brand Innovator Awards.
2012: Diagnostic Service Provider Company of the Year, by Frost & Sullivan at the 4th Annual India Healthcare Excellence Awards.
2012: Named a Computerworld Honours Laureate by the Computerworld Honours Program for innovative use of information technology to conduct research, develop new diagnostic methods and services and improve quality and access of patients to healthcare.
2013: Best Diagnostic Company in India at the VC Circle Healthcare Summit.
2014: Received the ISO 27001:2013 certification for the information management system for providing data center services and supporting functions.
2014: Received an NABL certificate of accreditation under standard ISO 15189:2012 for “Medical Laboratories - Requirements for Quality and Competence” for medical testing, for National Reference Laboratory.
2015: Data Quest Technology Award for Excellence in the implementation and use of technology for business benefits in the ‘Cloud’ category.
2015: Received the certificate of affiliation from the Healthcare Sector Skill Council for role as medical laboratory technician in relation to institute at Gurgaon, Haryana, India.

Major events and milestones

2005, 2007: Investment by WestBridge I Investments Holdings.
2008: Acquisition of Paliwal Medicare and Paliwal Diagnostics.
2010: Establishment of its National Reference Laboratory.
2010, 2013: Investment pursuant to purchase of shares by Wagner Limited from WestBridge I Investment Holdings.
2013: Investment pursuant to purchase of shares by WestBridge Crossover Fund, LLC from WestBridge I Investment Holdings.
2013: Investment by SIH.
2014: Acquisition of APL Clinical Institute of Clinical Laboratory & Research.
2015: Amalgamation of Sanya Chemicals Private, Amolak Diagnostics, Medex Healthcare, Medicave Diagnostic Centre, Medicave Medical Systems and the company.
2016: the Parent Company has set up new/acquired laboratories at various locations in India and some new patient service centers at various locations.
2017: The Company had acquired 10% addiOonal equity stake in its exisOng two subsidiaries - Paliwal DiagnosOc Private Limited (PDPL) and Paliwal Medicave Private Limited (PMPL).
2017: the Company has acquired 100% equity stake in “Delta Ria and Pathology Private Limited”, engaged in the business of providing pathological diagnosOcs services in Bhopal.
2019: Company’s Wholly Owned Subsidiary viz M/s PathLabs Unifiers Private Limited acquired 70% equity stake in M/s Centrapath Labs Private Limited and M/s APRL PathLabs Private Limited consequent upon which both these Companies became subsidiaries of the Company.
2019: The company acquired 70% equity stake in “APRL PathLabs Private Limited”, engaged in the business of providing pathological diagnostics services, on a going concern basis.